EGFR and non-small cell lung carcinoma: Pembrolizumab was the first immune checkpoint inhibitor (ICI) approved as a single agent in the first-line setting in advanced NSCLC patients with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations and high expression levels of PD-L1 (tumor proportion score, TPS ≥ 50%) [9,10]—which accounts for almost one-third of advanced NSCLC patients.